Introduction Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated severe clinical outcomes. MicroRNA (miR)-210 has been reported to be related T2DM and lipid metabolism. This study aimed determine whether miR-210 can predict the effects of glimepiride linagliptin on NAFLD T2DM. Material methods A total 86 patients were randomly categorized into two groups ...

Type 2 diabetes has become a major burden to the health care systems worldwide. Among the drugs approved for this indication, glimepiride and rosiglitazone have gained substantial importance in routine use. While glimepiride stimulates beta-cell secretion and leads to reduction of blood glucose values, rosiglitazone activates PPARgamma and improves insulin resistance, at the vascular and metabo...

Background: Several recent studies have shown that treatment with therapeutic lifestyle changes, and/or several drugs retard progression of prediabetes to type 2 diabetes. However, none of these studies used a Sulfonylurea (SU), although in UKPDS, SUs delayed the progression of hyperglycemia and several subjects would have been categorized as having prediabetes by present diagnostic criteria. T...

Hyperglycaemia is most probably a contributing factor in the development of ischaemic acute renal failure (ARF) in many patients. Both clinical and experimental data suggest that hyperglycaemia increases the risk of ARF. Present study was designed to evaluate in Glimepiride reduced on experimentally induced ischemia/reperfusion in diabetic rats. Type 2 Diabetes was induced in rats by a single i...

BACKGROUND Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease. Carotid intima-media thickness (IMT) is a strong predictor of myocardial infarction and stroke. METHODS AND RESULTS We compared the effects of pioglitazone-based therapy (45 mg/d) and glimepiride-based treatment (2.7+/-1.6 mg/d) for 12 and 24 weeks on metabolic control (HbA1c), insulin resistance (ho...

OBJECTIVE Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in a broad range of patients with T2DM. This post hoc analysis assessed the effects of canagliflozin...

Objective: The objective of present study deals with an attempt to formulate Glimepiride in liposomal drug delivery system, in order to maintain steady state plasma concentration; hence it has to be administered frequently to the patients, because of its short plasma half life. To maintain steady plasma concentration for longer period of time formulation of controlled drug release system is ess...

BACKGROUND To observe the efficacy and safety of adding glimepiride to established insulin therapy in poorly controlled type 2 diabetes (T2D) and to assess the relationship of changes in the serum high-molecular weight (HMW) adiponectin levels and glycemic control after glimepiride treatment. METHODS Fifty-six subjects with poorly controlled insulin-treated T2D were randomly assigned to eithe...

A stability indicating RP-HPLC method was developed and validated for the determination of Metformin HCl and Glimepiride in tablet dosage form. The method was carried out using Agilent C18 column (250 mm×4.6 mm, 5 μ) with mobile phase consisting 25 mM Hexane-1-sulphonic acid buffer adjusted to pH 2.5 with ortho-phosphoric acid and acetonitrile (45:55 v/v), at a flow rate of 1.0 mL/min and the e...

OLETF (Otsuka Long-Evans Tokushima Fatty) rats are characterized by obesity-related insulin resistance, which is a phenotype of type 2 diabetes. Sulfonylurea drugs or benzoic acid derivatives as inhibitors of the ATP-sensitive potassium (K(ATP)) channel are commercially available to treat diabetes. The present study compared sulfonylurea drugs (glimepiride and gliclazide) with one of benzoic ac...